Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Protocol ID
INFORM2 NivEnt
Disease (Sub Disease)
CNS Tumour
Solid Tumour
Solid Tumour
Diagnosis Stage
Recurrent/ refractory
Location
NSW, VIC, WA
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
University Hospital Heidelberg
University Hospital Heidelberg
Collaborators
German Cancer Research Center
Links
Trial Status
Open
Sites
Perth Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
The Children's Hospital at Westmead
Sydney Children's Hospital
Royal Children's Hospital
The Children's Hospital at Westmead
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
6 Years to 21 Years
International registry ID's
NCT03838042
| Study Title | Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies |
|---|---|
| Protocol ID | INFORM2 NivEnt |
| Disease (Sub Disease) | CNS Tumour Solid Tumour |
| Diagnosis Stage | Recurrent/ refractory |
| Location | NSW / VIC / WA |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ University Hospital Heidelberg |
| Collaborators | German Cancer Research Center |
| Links | https://clinicaltrials.gov/ct2/show/NCT03838042 |
| Trial Status | Open |
| Trial Open Date | 26/07/2019 |
| Sites | Perth Children's Hospital / Sydney Children's Hospital / Royal Children's Hospital / The Children's Hospital at Westmead |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 6 Years to 21 Years |
| International registry ID's | NCT03838042 |